je.st
news
Home
› FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-04-29 05:21:48| drugdiscoveryonline Home Page
Dicerna Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, recently announced that the U.S
Tags: type
primary
treatment
drug
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||